Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia

Outcomes for those diagnosed with acute myeloid leukemia (AML) remain poor. It has been widely established that persistent residual leukemic burden, often referred to as measurable or minimal residual disease (MRD), after induction therapy or at the time of hematopoietic stem cell transplant (HSCT)...

Descripción completa

Detalles Bibliográficos
Autores principales: Roloff, Gregory W., Lai, Catherine, Hourigan, Christopher S., Dillon, Laura W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615280/
https://www.ncbi.nlm.nih.gov/pubmed/28925935
http://dx.doi.org/10.3390/jcm6090087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615280/
https://www.ncbi.nlm.nih.gov/pubmed/28925935
http://dx.doi.org/10.3390/jcm6090087

Ejemplares similares